Labcorp Holdings Inc. (CH:LH)
NYSE:LH
LH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationSustained and improving free cash flow provides durable financial optionality: it funds capital expenditures (~4% of revenue guidance), dividends, M&A and buybacks while supporting deleveraging. Over 2–6 months this underpins balance-sheet flexibility and strategic investments.
Robust BLS Backlog And Book-to-billA large, visible Biopharma Lab Services backlog and >1.0 book-to-bill give multi-quarter revenue visibility and support margin leverage as contracted trials convert. This durable pipeline cushions organic volatility and sustains outsourcing-driven revenue for the coming 12 months.
Diagnostics Scale And Margin ExpansionRecurring clinical testing with scale across a large lab network, steady organic volumes and ongoing price/mix gains support structural margins. Operational improvements and mix shifts toward higher-margin specialty assays help sustain operating profitability over the medium term.
Bears Say
Regulatory And Reimbursement RiskUncertain reimbursement policy outcomes (PAMA/RESULTS Act, CRUSH) threaten pricing and test access across diagnostics. These structural regulatory risks can compress margins or reduce volumes for specific assays for many quarters, making revenue and margin forecasts less certain.
Elevated Leverage And Covenanted Term LoanMaterial debt and a recently funded $750M term loan increase near-term leverage and impose covenant limits that can restrict capital allocation. This constrains M&A, buybacks or aggressive reinvestment if free cash flow underperforms, affecting strategic flexibility over multiple quarters.
Profitability And Cash Conversion Below Historic PeaksMargins and cash conversion remain meaningfully below 2021–2022 peaks, indicating structural pressures (pricing, mix, reimbursement). Lower cash conversion relative to net income raises earnings quality questions and limits rapid balance-sheet repair if headwinds persist.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings Inc.’s price range in the past 12 months?
Currently, no data Available
What is Labcorp Holdings Inc.’s market cap?
Currently, no data Available
When is Labcorp Holdings Inc.’s upcoming earnings report date?
Labcorp Holdings Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Labcorp Holdings Inc.’s earnings last quarter?
Labcorp Holdings Inc. released its earnings results on Apr 30, 2026. The company reported $3.397 earnings per share for the quarter, beating the consensus estimate of $3.285 by $0.112.
Is Labcorp Holdings Inc. overvalued?
According to Wall Street analysts Labcorp Holdings Inc.’s price is currently Undervalued.
Does Labcorp Holdings Inc. pay dividends?
Labcorp Holdings Inc. does not currently pay dividends.
What is Labcorp Holdings Inc.’s EPS estimate?
Labcorp Holdings Inc.’s EPS estimate is 3.83.
How many shares outstanding does Labcorp Holdings Inc. have?
Currently, no data Available
What happened to Labcorp Holdings Inc.’s price movement after its last earnings report?
Labcorp Holdings Inc. reported an EPS of $3.397 in its last earnings report, beating expectations of $3.285. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Labcorp Holdings Inc.?
Currently, no hedge funds are holding shares in CH:LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$250.39 (― Downside)
$250.39 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.75%
12-Months-Change
Fundamentals
Return on Equity
10.91%
Trailing 12-Months
Asset Growth
8.43%
Trailing 12-Months
Company Description
Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Company Deck
LH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: solid top-line growth, double-digit EPS improvement, margin expansion, healthy BLS backlog and raised/narrowed guidance. Management highlighted strong progress on strategic partnerships, product launches and AI/technology initiatives. Key challenges include weather-driven volume disruption, Early Development transitional actions, regulatory/reimbursement uncertainty (CRUSH, PAMA/RESULTS Act), and modest short-term cash flow/leverage considerations. Overall, positives around organic growth, profitability and a robust deal/product pipeline outweigh the identified headwinds.View all CH:LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
LH Stock 12 Month Forecast
Average Price Target
$250.39
Options Prices
Currently, No data available
---